Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 9/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26086786 | 1.00 | HCRTR2 (0.43) | HCRTR2HCRTR1SLC6A7KDM4EALDH1A1 | |
| SCHEMBL27233863 | 0.77 | GPR119 (0.41) | SLC6A7TSHR | |
| SCHEMBL27233797 | 0.77 | GPR119 (0.41) | SLC6A7TSHR | |
| SCHEMBL29165926 | 0.77 | GPR119 (0.41) | SLC6A7TSHR | |
| SCHEMBL27233842 | 0.77 | GPR119 (0.41) | SLC6A7TSHR | |
| SCHEMBL26089901 | 0.75 | HCRTR2 (0.50) | HCRTR2HCRTR1SLC6A7KDM4EALDH1A1 | |
| SCHEMBL26090124 | 0.74 | HCRTR1 (0.37) | HCRTR2HCRTR1ALDH1A1TSHR | |
| SCHEMBL26087364 | 0.73 | GPR119 (0.40) | HCRTR2HCRTR1SLC6A7 | |
| SCHEMBL29165847 | 0.72 | GPR119 (0.40) | SLC6A7KDM4ETSHR | |
| SCHEMBL29165849 | 0.72 | GPR119 (0.40) | SLC6A7KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | HCRTR2 183/4885HCRTR1 210/4885SLC6A7 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.